KyrgyzstanTuberculosis profile
Population  2015 5.9 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.68 (0.67–0.7) 12 (11–12)
Mortality (HIV+TB only) 0.044 (<0.01–0.14) 0.74 (0.05–2.4)
Incidence  (includes HIV+TB) 8.5 (7.1–10) 144 (120–170)
Incidence (HIV+TB only) 0.26 (0.17–0.37) 4.4 (2.8–6.3)
Incidence (MDR/RR-TB)** 5 (4.1–5.9) 84 (69–99)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.39 (0.2–0.59) 3.2 (2.2–4.1) 3.6 (2.4–4.7)
Males 0.48 (0.32–0.64) 4.5 (3.5–5.5) 5 (3.8–6.2)
Total 0.88 (0.65–1.1) 7.7 (6.8–8.5) 8.5 (7.1–10)
TB case notifications, 2015  
Total cases notified 7 833
Total new and relapse 7 027
          - % tested with rapid diagnostics at time of diagnosis 21%
          - % with known HIV status 96%
          - % pulmonary 74%
          - % bacteriologically confirmed among pulmonary 61%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 82% (70–99)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.09 (0.07–0.1)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 206 3%
          - on antiretroviral therapy 194 94%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  2 400
(2 200–2 600)
Estimated % of TB cases with MDR/RR-TB 32% (28–36) 56% (53–59)  
% notified tested for rifampicin resistance 33% 50% 2 946
MDR/RR-TB cases tested for resistance to second-line drugs   235
Laboratory-confirmed cases MDR/RR-TB: 1 116, XDR-TB: 54
Patients started on treatment **** MDR/RR-TB: 1 158, XDR-TB: 50
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 84% 5 731
Previously treated cases, excluding relapse, registered in 2014 79% 915
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 57% 1 064
XDR-TB cases started on second-line treatment in 2013 28% 43
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 3%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
46% (43–51)
TB financing, 2016  
National TB budget (US$ millions) 20
Funding source: 60% domestic, 26% international, 14% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data